Status:
COMPLETED
SUTENT® In The First Line Treatment Of Renal Cell Carcinoma
Lead Sponsor:
Pfizer
Conditions:
Renal Cell Carcinoma
Eligibility:
All Genders
Brief Summary
This non-interventional study includes patients with advanced and/or metastatic renal cell carcinoma who are treated with SUTENT and who did not receive any other systemic therapy before. The aim of t...
Detailed Description
The Statistical Analysis Plan provides detailed specification of the analysis
Eligibility Criteria
Inclusion
- First-line treatment in patients with metastatic renal cell carcinoma
Exclusion
- Any previous systemic therapy of renal cell carcinoma except for adjuvant treatment
Key Trial Info
Start Date :
February 1 2007
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 1 2009
Estimated Enrollment :
356 Patients enrolled
Trial Details
Trial ID
NCT00460798
Start Date
February 1 2007
End Date
September 1 2009
Last Update
November 16 2010
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.